Functional and Structural Properties of a Novel Protein and Virulence Factor (Protein sHIP) in *Streptococcus pyogenes*

Received for publication, March 15, 2014, and in revised form, May 3, 2014. Published, JBC Papers in Press, May 13, 2014. DOI 10.1074/jbc.M114.565978

Magdalena Wisniewska1,2, Lotta Happonen1,2, Fredrik Kahn3, Markku Varjosalo4, Lars Malmström5, George Rosenberger6, Christofer Karlsson5, Giuseppe Cazzamali7, Irina Pozdnyakova8, Inga-Maria Frick5, Lars Bjöörk6, Werner Streicher6, Johan Malmström7,8, and Mats Wikström4,9

From the 1Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200 Copenhagen, Denmark, the 2Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden, the 3Institute of Biotechnology, Viikinkaari 1, University of Helsinki, FI-00014 Helsinki, Finland, and the 4Department of Biology, ETH Zürich, 8093 Zürich, Switzerland

**Background:** We searched for novel extracellular proteins in *Streptococcus pyogenes*. A protein (sHIP) protecting *S. pyogenes* against antibacterial activity was identified. Its structure was determined, and severe *S. pyogenes* infections were connected with elevated antibody titers against this protein.

**Conclusion:** We identified a protein with unique structure and impact on *S. pyogenes* virulence.

**Significance:** This work increases our understanding of *S. pyogenes* pathogenesis.

*Streptococcus pyogenes* is a significant bacterial pathogen in the human population. The importance of virulence factors for the survival and colonization of *S. pyogenes* is well established, and many of these factors are exposed to the extracellular environment, enabling bacterial interactions with the host. In the present study, we quantitatively analyzed and compared *S. pyogenes* proteins in the growth medium of a strain that is virulent to mice with a non-virulent strain. Particularly, one of these proteins was present at significantly higher levels in stationary growth medium from the virulent strain. We determined the three-dimensional structure of the protein that showed a unique tetrameric organization composed of four helix-loop-helix motifs. Affinity pull-down mass spectrometry analysis in human environment, this suggests that there could be additional proteins interacting with the human host with an impact on the pathogenesis. Functional and Structural Properties of a Novel Protein and Virulence Factor (Protein sHIP) in *Streptococcus pyogenes*

**Results:** A protein (sHIP) protecting *S. pyogenes* against antibacterial activity was identified. Its structure was determined, and severe *S. pyogenes* infections were connected with elevated antibody titers against this protein.

**Conclusion:** We identified a protein with unique structure and impact on *S. pyogenes* virulence.

**Significance:** This work increases our understanding of *S. pyogenes* pathogenesis.

*Streptococcus pyogenes* is a significant bacterial pathogen in the human population. The importance of virulence factors for the survival and colonization of *S. pyogenes* is well established, and many of these factors are exposed to the extracellular environment, enabling bacterial interactions with the host. In the present study, we quantitatively analyzed and compared *S. pyogenes* proteins in the growth medium of a strain that is virulent to mice with a non-virulent strain. Particularly, one of these proteins was present at significantly higher levels in stationary growth medium from the virulent strain. We determined the three-dimensional structure of the protein that showed a unique tetrameric organization composed of four helix-loop-helix motifs. Affinity pull-down mass spectrometry analysis in human plasma demonstrated that the protein interacts with histidine-rich glycoprotein (HRG), and the name sSHIP (streptococcal histidine-rich glycoprotein-interacting protein) is therefore proposed. HRG has antibacterial activity, and when challenged by HRG, sSHIP was found to rescue *S. pyogenes* bacteria. This and the finding that patients with invasive *S. pyogenes* infection respond with antibody production against sSHIP suggest a role for the protein in *S. pyogenes* pathogenesis.

*S. pyogenes* is a strict human pathogen, but there are rare isolates that cause invasive infections in mice. One of these is the AP1 strain (21) of the M1 serotype, a serotype that has dominated in cases of severe invasive infections since the 1980s. SF370, the first *S. pyogenes* strain where the complete genome sequence was determined (22), is also an M1 strain but shows a low degree of virulence in mice (23), and the lethal dose is 100-fold higher than for AP1. When injected intraperitoneally, 106 SF370 bacteria cause 100% lethality in mice (24) whereas 108 SF370 bacteria intraperitoneally leave mice unaffected. In this study, we performed a mass spectrometry (MS) screen in order to compare the presence of so far unknown proteins in the
Structure and Function of Protein sHIP

growth medium from highly virulent AP1 bacteria with the medium from the SF370 strain. In particular, one protein (UniProtKB ID Q99XU0) was found at significantly higher levels in the extracellular pool of the AP1 strain. We have performed thorough functional and structural characterization of this protein, including the determination of the high-resolution crystal structure. Affinity pull-down mass spectrometry (APMS) studies in human plasma using sHIP as bait identified histidine-rich glycoprotein (HRG), a plasma protein with established antibacterial activity against S. pyogenes (24), as a prominent ligand for the protein. Therefore, the name sHIP (streptococcal histidine-rich glycoprotein-interacting protein) was introduced. The antibacterial activity of HRG was blocked by sHIP, a mechanism that could contribute to the virulence of AP1 bacteria. This notion was further supported by the observation that patients with severe invasive S. pyogenes infections, in contrast to patients with uncomplicated superficial infections, develop elevated antibody titers against sSHIP.

EXPERIMENTAL PROCEDURES

Bacterial Culture Conditions and Sample Preparation— S. pyogenes M1 strain AP1 (strain 40/58 from the World Health Organization Collaborating Centre for Reference and Research on Streptococci, Prague, Czech Republic) was grown at 37 °C, 5% CO2 in protein-reduced Todd-Hewitt (TH) broth (25). Samples of cells and medium from 10–ml cultures were collected in triplicates at 0, 1.5, 3, 4.5, 6, 7.5, and 9 h. The optical density at 620 nm (A620 nm) of these cultures was measured, and the number of bacterial cells was quantified by plating serial dilutions of the cultures on TH agar. Plates were incubated overnight at 37 °C in 5% CO2, and the colony-forming units/ml were determined. The medium samples were concentrated to 350 μl by ultrafiltration (Millipore-Amicon ultracentrifugation filter units, 10 kDa molecular mass cut-off) prior to SRM-MS analysis. The cell pellets were suspended in LC-H2O into a 1% bacterial suspension prior to cell homogenization in a cell disruptor (Mini-Beadbeater-96, Bio Spec) and subsequent sample preparation for SRM-MS analysis. Samples for SRM-MS were reduced, alkylated, digested with trypsin, and purified using C18 reverse phase spin columns as described (see “Affinity Pull-down and Sample Preparation for Liquid Chromatography Mass Spectrometry”).

SRM-MS—Identified peptides from sHIP (LANLIEALDAF), M1 protein (LENAMEVAGR, ALEAIDQAOSQDYNR, and EVIEDLAANPAIQNQR), protein H (LVEVVTSSLNEK), and protein SmeZ (SNJPNVNLWINR) (26, 27) were synthesized as heavy labeled variants (JPT Technologies (Berlin, Germany) or Aqua QuantPro, Thermo Fisher Scientific), and the known concentrations were used to absolutely quantify the peptides.

The SRM-MS measurements were performed as described previously (28).

Determination of Protein sHIP on the Surface of AP1 Bacteria—Protein G, a 17-kDa fragment containing the IgG-binding region, was purchased from GE Healthcare and radiolabeled with 125I using IODO-BOE Iodination reagent (Pierce) as described by the manufacturer. S. pyogenes AP1 bacteria were grown in protein-reduced TH broth to stationary phase, washed, and diluted to 2 × 108 cfu/ml in PBS. The rabbit antisera against the recombinant protein sHIP was produced by BioGenes GmbH (Berlin, Germany). A 200-μl bacterial solution was incubated with 10 μl of preimmune serum or anti-sHIP antiserum, diluted 1:1000 for 1 h at room temperature. The bacteria were then washed with PBS, resuspended in 200 μl of PBST (PBS + 0.05% Tween 20), and incubated with 25 μl of 125I-labeled protein G for 30 min at room temperature. Following a washing step with PBST, bacteria-bound radioactivity was determined.

Protein Expression and Purification—The DNA sequence corresponding to residues Lys2–Met181 in the S. pyogenes protein sHIP (UniProtKB ID Q99XU0) was introduced into the expression vector pNIC-Bsa4 in the S. pyogenes protein sHIP (UniProtKB ID Q99XU0) and subsequently transformed into E. coli strain Rosetta (DE3) (29). In addition, a mutant protein corresponding to the single site mutation C65S was constructed. The resulting expression constructs contained either a His tag (biophysics, structural studies, and antibody production) or a TAP tag (His-HA-StrepII tag, MS interactome studies) and a tobacco etch virus protease cleavage site at the N terminus. Escherichia coli cells were cultured in Terrific Broth medium with 50 μg/ml kanamycin. Protein expression was induced with 0.5 mM isopropyl-β-thiogalactopyranoside, and cell growth was continued for 18 h at 18 °C. Harvested bacterial pellets were suspended in lysis buffer (100 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 0.5 mM TCEP) complemented with EDTA-free protease inhibitor and ruptured using a French press cell disruptor. Cell debris and membrane components were removed by centrifugation at 40,000 × g for 1 h. sHIP was produced in four variants, two variants of the wild-type protein (His tag and TAP tag), the C65S mutant (His tag), and a selenomethionine-labeled wild-type variant (His tag) using minimal medium for cell growth. Purification of the proteins was performed in two steps using immobilized metal ion affinity chromatography on an ÄKTA express system (GE Healthcare) at 4 °C with the HiTrap chelating columns (30). Subsequently, the proteins were purified using reverse phase chromatography on a Dionex Ultimate 3000 HPLC system equipped with a preparative C18 HPLC column (Gemini NX, Phenomenex). The proteins were eluted by a linear gradient of 10–60% acetonitrile, flash-frozen, and lyophilized. Lyophilized proteins were dissolved in crystallization buffer (5 mM Tris, pH 7.5, 50 mM NaCl) and stored at −80 °C for further analysis. For the proteins used in the biophysical and structural studies and for antibody production, the His tag was removed by treatment with tobacco etch virus protease followed by reverse phase chromatography purification, giving the following amino acid sequence: SMKQDQLIVEKMEQTYEAFSPKLALNEALDAFKEHYEEYATLRNFYSSDEWFRLANQ-
PWDDIPCGVLSEDILFDMLGDIQLQLAPIMY-KHM. HRG cDNA (UniProtKB ID P04196) was cloned into the
Structure and Function of Protein sHIP

strepII C-terminal vector pCEP4-CTStrepII using ligation-independent cloning (29). The plasmid was transformed into Mach1-T1 cells (Invitrogen), and 2.7 liters of overnight culture was prepared with the Nucleobond PC 10000 EF kit (Macherey-Nagel). The transfection was performed in human embryonic kidney EBNA cell lines (HEK293 6E) grown in serum-free Freestyle F17 medium (Invitrogen). One day prior to transfection, HEK293 6E cells were resuspended in fresh Freestyle F17 medium to a cell density of 1.2 × 10⁶ cells/ml and incubated at 37 °C overnight. Before transfection, cells were resuspended in 50 ml of fresh Freestyle F17 expression medium at a cell density of 20 × 10⁶ cells/ml and incubated in an orbital shaker incubator at 37 °C, 70% humidity, 5% CO₂, and 120 rpm until completion of the transfection. 5000 µg of of DNA (50 µg/ml final) and 10 µl of polyethyleneimine MAX (Polysciences) (100 µg/ml solution final) were directly added to the cell suspension. 1950 ml of Freestyle F17 medium was added to a final volume of 2 liters of cell suspension, 4 h post-transfection. TN1 (Invitrogen) additive was added to a final concentration of 0.5% 24 h post transfection. Five days post-transfection, the supernatant was collected by centrifugation at 6500 rpm for 10 min at 4 °C and concentrated using a SARTOFLOW System, with a Hydrosart 10 kDa molecular mass cut-off (3081443902E-SG, Sartorius) to a volume of 100 ml at 4 °C. The concentrated solution was centrifuged at 27,000 × g and filtered through a 0.2-µm membrane. The concentrated solution was injected into an IBA Strep-Tactin Superflow high capacity column (IBA 2-1234-001) for purification of the Strep-tagged protein. The standard protocol and buffers recommended by IBA was used. The purity and monodispersity of the proteins were confirmed by SDS-PAGE and mass spectrometry.

Affinity Pull-down and Sample Preparation for Liquid Chromatography Mass Spectrometry—For affinity pull-down, Strep-Tactin Sepharose beads (IBA) were equilibrated in PBS buffer, pH 7.4, and charged with 20 µg of recombinant, TAP-tagged sHIP. Pooled normal human plasma from healthy donors ( Innovative Research) (200 µl) was incubated with protein sHIP charged beads at 20 and 37 °C and 800 rpm for 1 h. The beads were washed with 4 ml of ice-cold PBS buffer, pH 7.4, at 4 °C, and sHIP protein was eluted with bound proteins using 120 µl of 5 mM biotin. An equal amount of 8 mM urea and 100 mM NH₄HCO₃ was added, and the cysteine bonds were reduced with 5 mM TCEP (37 °C 1 h) and alkylated with 10 mM iodoacetamide (22 °C 30 min). The sample was diluted with 100 mM ammonium bicarbonate to a final urea concentration of 1.5 M, and trypsin was added for protein digestion (37 °C, 18 h). The peptides were purified with C18 reverse phase spin columns according to the manufacturer’s instructions (Microspin columns, Nest Group).

Crystallography, X-ray Data Collection, and Structure Determination—Crystallization of sHIP was carried out using the sitting drop vapor diffusion method at 18 °C. The best native and selenomethionine crystals were obtained from 20% PEG 3350, 0.2 M sodium malonate, and 0.1 M BisTris propane, pH 7.5. Prior to plunge freezing, the crystals were soaked for ~30 s in a drop of a reservoir solution containing 20% (v/v) ethylene glycol as cryoprotectant. The crystals belonged to the space group P1211 and contained four monomers per asymmetric unit. Both native and derivative data sets were collected at BESSY (BL14-1) (Berlin, Germany). Data were indexed and integrated using XDS (31) or iMOSFLM (32) and scaled using XSHELL (31) or SCALA (33) from the CCP4 suite. The structure was solved by single isomorphous replacement with anomalous scattering using autoSHARP (34) and refined using REFMAC (35). Refinement rounds were complemented with manual rebuilding using COOT (36). For further details on data processing and refinement statistics, see Table 1. Geometry of the model was analyzed with Molprobity (37). Structural similarity searches were carried out using the Dali server (38), where Z-scores of >5 were kept as significant. Figures were generated using the program PyMOL. The protein sequence comparisons were performed using BLAST (39), and the overall geometry for the helical segments was characterized by the program HELANAL-Plus (40).

Liquid Chromatography Mass Spectrometry—The lyophilized peptides were reconstituted (2% acetonitrile, 0.2% formic acid), and the MS analysis was performed on an Orbitrap Elite ETD mass spectrometer (Thermo Scientific), using Xcalibur version 2.2, coupled to a Thermo Scientific nLCII nanoflow HPLC system. Solvents for LC separation of the digested samples were as follows. Solvent A consisted of 0.1% formic acid in water (98%) and acetonitrile (2%), and solvent B consisted of 0.1% formic acid in acetonitrile (98%) and water (2%). From a thermostat-controlled microautosampler, 2 µl of the tryptic peptide mixture (corresponding to 7% of the eluate) was automatically loaded onto a 15-cm fused silica analytical column (PicoFrit, New Objective) with an inner diameter of 75 µm packed with C18 reverse phase material, and the peptides were eluted from the analytical column with a 40-min gradient ranging from 5 to 35% solvent B followed by a 10-min gradient from 35 to 80% solvent B at a constant flow rate of 300 nl/min. The analyses were performed in a data-dependent acquisition mode using a top 20 collision-induced dissociation type of method. Dynamic exclusion for selected ions was 30 s. No lock masses were used in the study.

Protein Identification and Label-free Quantification—The spectra were searched using the search engines X! Tandem (version 2010.12.01.1) (41) and OMSSA (version 2.1.9) (42) against the concatenated database of the S. pyogenes AP1 draft genome and a human FASTA database using fully tryptic digestion and allowing 1 missed cleavage. Included were “Carbamidomethyl (C)” as static and “Oxidation (M)” as variable modifications. The mass tolerances were set to 30 ppm for precursor ions and 0.4 Da for fragment ions. The identified peptides were processed and analyzed through the Trans-Proteomic Pipeline (version 4.6.0) using PeptideProphet, iProphet, and ProteinProphet scoring (43, 44). Label-free quantification using spectral counts was conducted using an in-house developed script: all peptide spectrum matches (PSMs) above an iProphet probability >0.9 were selected, corresponding to a protein false discovery rate of ≤1%. Protein inference was conducted by computing the total spectral count of all reported peptides per protein.

Identification and Assessment of Significance of Interactions—To identify the protein-protein interactions, SAINT (version 2.3.4) (45) and a custom implementation of CompPASS were...
Structure and Function of Protein sHIP

used (46). SAINT was used individually per biological condition (plasma 20 °C or plasma 37 °C) with parameters described previously (47) (saint-spc-ctrl, nburnin = 2000, niter = 10,000, lowMode = 0, minFold = 1, normalize = 1), using three technical replicates and the three associated, individual control runs. Results with a score AvgF ≥ 0.95 were considered to be of high confidence. The custom CompPASS implementation was used to compute the D score individually per biological condition (plasma 20 °C or plasma 37 °C) for three technical replicates and the three associated, individual control runs. To normalize the score, we permuted the prey and bait identifiers in the input table 20 times with replacing and selected the 95% quantile as threshold D\text{7}. The D score was normalized by the threshold D\text{7}, resulting in the D\text{8} score. Interactions with a D\text{8} score ≥1, were considered to be of high confidence.6

Slot-binding Analysis—AP1 bacteria were cultivated at 37 °C, 5% CO₂ in protein-reduced TH broth, and at time points 4.5, 6, 7.5, and 9 h the growth medium was collected and sterile filtered. One ml of the medium was applied to PVDF membranes (Amersham Biosciences) using a Milliblot-D system (Millipore). Membranes were blocked in PBST (PBS + 0.05% Tween 20) containing 5% dry milk powder (blocking buffer) and incubated with primary antibody (rabbit anti-sHIP 1:1000) or pre-immune rabbit serum (1:1000) in blocking buffer for 30 min at 37 °C. Following a washing step with PBST, the membranes were incubated with secondary antibodies (HRP-conjugated goat anti-rabbit IgG 1:5000, purchased from Bio-Rad) in blocking buffer for 30 min at 37 °C. The membranes were washed, and bound antibodies were detected by chemiluminescence.

Peptides—The sequences for the two HRG peptides used in the study are derived from the histidine-rich region of HRG (48) and have the following sequences: HRG short peptide (HRGsp), GHHPGHPPHG; HRG long peptide (HRGlp), GHHPGHPPHGHPHPPH. The peptides were synthesized by Biosyntan GmbH (Berlin, Germany). Purity and molecular mass were confirmed by MALDI-TOF MS.

Analytical Ultracentrifugation—To provide a quantitative analysis of the oligomeric states of the proteins, analytical ultracentrifugation was employed. Sedimentation velocity experiments were performed at 20 °C and 50,000 rpm using a Beckman XL-I instrument. Samples were in 25 mM MES buffer, pH 5.5 (WT sHIP and C65S mutant) or 25 mM HEPES buffer, pH 7.5 (WT sSHIP with 0.5 mM TCEP or without). The data were analyzed with SEDFIT using a continuous c(S) distribution (49). HYDROPRO (50) was used to calculate the theoretical sedimentation coefficient using the Protein Data Bank accession code for sSHIP, 4MER.

Surface Plasmon Resonance (SPR; Biacore)—Analysis of the molecular interactions between sSHIP and HRG, streptococcal protein G, and human ubiquitin, respectively, was performed on a Biacore T200 instrument (GE Healthcare). HRG (Creative BioMart), protein G (Sigma-Aldrich), or ubiquitin (Boston Biochem) was immobilized on a CM3 sensor chip using standard amine coupling at pH 5.0 in 10 mM acetate buffer at two different immobilization levels (1000 and 2000 response units). All binding experiments were performed at 25 °C in Dulbecco’s PBS buffer, pH 7.3 (Biowest) at two flow rates, 30 and 60 μl/min. Prior to binding experiments, sSHIP protein was extensively dialyzed into Dulbecco’s PBS buffer. sSHIP was injected at concentrations ranging from 4 to 100 μM with a contact time of 60 s, and dissociation was monitored for 120 s. The surfaces were regenerated with a 60-s injection of regeneration buffer (50 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole, pH 8.0) followed by a 30-s injection of 50 mM NaOH at a flow rate of 30 μl/min. All data were double-referenced and analyzed using the BIAevaluation analysis package.

Isothermal Titration Calorimetry (ITC)—ITC experiments were performed using a VP-ITC200 instrument (GE Healthcare). The samples were prepared by extensively dialyzing sSHIP, HRGsp, and intact recombinant HRG against 25 mM MES, pH 5.5, buffer or sSHIP and intact HRG against 25 mM HEPES, pH 7.5, buffer. In the experiments using intact HRG, ~0.2 mM HRG was titrated into ~0.03 mM sSHIP. For the experiments employing the HRG peptide, a 0.5 mM concentration of the HRGsp was titrated into 50 μM sSHIP. All experiments were performed at 25 °C and run until saturation was achieved. The data were fitted using a model describing one binding site (intact HRG at pH 5.5) or two independent binding sites (intact HRG at pH 7.5 and HRGsp) using the software provided by the manufacturer (51).

Antibacterial Assay—S. pyogenes AP1 bacteria were grown to mid-log phase in TH broth, washed, and diluted to 2 × 10⁹ (cfu/ml) in 10 mM Tris-HCl, pH 7.5, containing 5 mM glucose. The bacterial cells were then further diluted in 10 mM MES buffer, pH 5.5, containing 5 mM glucose. A 50-μl bacterial solution (2 × 10⁹ cfu/ml) was incubated with full-length HRG or the HRGlp at various concentrations for 40 min at 37 °C. In subsequent experiments, bacteria were incubated with bactericidal concentrations of full-length HRG or the HRGlp together with various concentrations of protein sSHIP. The bactericidal activity was quantified by plating serial dilutions of the incubation mixtures on TH agar and incubating them overnight at 37 °C, after which the number of cfu was determined.

Patients—Patients with invasive (n = 6) or non-invasive (eight cases of erysipelas) S. pyogenes infection were included. In cases of invasive infection, S. pyogenes was isolated from the blood of five patients. In one case of necrotizing fasciitis, the diagnosis was determined clinically during operation and serologically by increased antibody titers against sSHIP and streptolysin O. To verify that S. pyogenes was the causative agent in the group of patients with erysipelas, one or several of the following criteria had to be met: isolation of S. pyogenes from the skin lesion or significantly raised antibody titers against DNase B, streptolysin O, or sSHIP. Acute and convalescent sera were analyzed from all patients. Acute sera were taken within 7 days after admittance up to 213 days before admittance to hospital.

Ethics Statement—All human samples used in this study were anonymized, and the patients had given their informed consent. The ethical review board of the Medical Faculty, Lund University, approved the study (LU 208-99).

ELISA Experiments—Microtiter plates (Maxisorb; NUNC) were coated overnight at 4 °C with sSHIP in coating buffer (50

---

6 Mass spectrometry data have been deposited and are available upon request. Protein interactions from this publication have been submitted to the IMEx consortium.
mm sodium bicarbonate, pH 9.6) at a concentration of 2 or 3 μg/ml. Plates were washed in PBST and blocked with 2% bovine serum albumin (Saveen Werner) in PBST. Serum samples from patients were diluted 1:100 in PBST with 2% bovine serum albumin and added to the wells. Bound antibodies were detected by incubation with horseradish peroxide-conjugated Protein G (Bio-Rad) at 1:2000 in PBST with 2% bovine serum albumin. All incubations were performed for 1 h at 37 °C and followed by a washing step. Substrate solution (0.1% (w/v) diaminonitrosyl salt, 0.012% (v/v) hydrogen peroxide in 100 mM citric acid, and 100 mM sodium dihydrogen phosphate (pH 4.5)) was added, and the optical density at 420 nm was determined. Each serum was added to the same plate in uncoated wells, and this optical density value was subtracted from the value obtained from the coated well. Polyclonal immunoglobulin G (Privigen; CSL Behring) (100 mg/ml) served as a standard and was serially diluted. From the serial dilution of Privigen, a standard curve was constructed, the optical densities from the different sera were compared against this standard curve, and the titers were determined. In patients that did not have a culture positive for S. pyogenes, acute and convalescent sera were checked for antibody titers against anti-streptococcal Dnase B and anti-streptolysin O to verify S. pyogenes as the cause of the infection. Anti-streptococcal Dnase B was performed as indicated by the manufacturer (Siemens Healthcare), and anti-streptolysin O was determined on a nephelometer (Immage800) with reagents from Beckman Coulter according to the instructions by the manufacturer.

**Statistical Evaluation**—The titers from the paired acute and convalescent sera were compared using the Wilcoxon signed rank test, and the difference of Protein G binding to AP1 bacteria preincubated with preimmune or anti-sHIP antiserum was analyzed by paired t test. For statistical calculation, GraphPad Prism version 6 was used. p < 0.05 was regarded as statistically significant.

**RESULTS**

**Identification of a Novel Uncharacterized Protein in the Growth Medium of S. pyogenes**—Stationary growth medium from two strains of *S. pyogenes* of the M1 serotype, one that is virulent when administered to mice (AP1) and one that is not (SF370), were subjected to an initial MS screen. In this screen, we identified a protein designated sHIP (UniProtKB ID Q99X0U) that was present at high relative abundance in the medium from the AP1 strain but at much lower concentration in SF370 medium (Fig. 1A). The gene encoding sHIP, identical in AP1 and SF370, is not unique to strains of the M1 serotype. Thus, when the genomes of M5 and M28 bacteria were analyzed (52, 53), sHIP proteins with identical protein sequences were identified also in these strains, suggesting that a highly conserved sHIP is present in all *S. pyogenes* strains. The majority of previously characterized virulence factors are either secreted or surface-associated. To ensure that sHIP is in fact a protein found in the extracellular compartment despite the absence of a predicted signal peptide (54), we cultured AP1 for 9 h and collected both growth media and a combined sample of intracellular and surface-associated proteins separately. Growth was followed by measurement of the optical density at 620 nm (A_{420}) and by counting the number of cfu (Fig. 1B). Samples of bacteria and growth medium were collected in triplicates at 1.5-h intervals, and the amount of sHIP in the samples was measured by SRM-MS using stable isotope-coded reference peptides (AQUA peptides). The heavy labeled peptides allow estimation of absolute protein amounts both in the bacterial lysate and in the growth medium, as described previously (55), which enables protein abundance comparisons of different proteins in the same sample (56). The amount of sHIP in the cell fraction was initially low (below the picomolar level) (Fig. 1C) but started to increase after 3 h at an A_{420} of 0.145. Simultaneously, the first traces of sHIP were detected in the culture medium using SRM-MS. The protein was also detected in the culture medium at 4.5 h by an antibody in slot binding experiments (Fig. 2). The amount of sHIP in the cell pellets and the medium continued to increase and after 9 h reached a level of 15 and 3 pm, respectively. Analogous to surface protein G and a number of housekeeping proteins in group G streptococci (57), the increase continued also after the culture had reached stationary growth phase (Fig. 1, B and C), demonstrating an active protein production in this phase. At 9 h, the ratio of sHIP between the cell and medium fractions was 5.9 (cell-associated/medium).

In order to relate the extracellular appearance of sHIP to proteins known to have a secretion signal and to be exported, we compared the abundance profile of sHIP with the profiles of the secreted streptococcal mitogenic exotoxin Z (SmeZ; Spy1998) (58) (Fig. 1C) and the surface-associated M1 protein (Spy2018) (3) and protein H (59) (Fig. 1D). SmeZ (and proteins M1 and H) contains a classical signal peptide and was detected only in the extracellular compartment (Fig. 1C). Whereas the amount of sHIP increased throughout the experiment, the amount of SmeZ in the culture medium reached saturation at a level of ~1 pm after 4.5 h. At 9 h, the amount of sHIP in the growth medium was 3 times higher than SmeZ. Moreover, based on the overall layout of the abundance profiles, the release of sHIP into the extracellular compartment followed that of M1 protein and protein H (Fig. 1D), of which both are surface-associated proteins known to be shed into the medium from the cell surface by the streptococcal cysteine protease SpeB (60). At 9 h, the ratio of the respective proteins between the cell-associated and medium fractions was 6.1 (cell-associated/medium) for M1 protein and 8.7 (cell-associated/medium) for protein H, both values close to the ratio we observed for sHIP. To investigate whether sHIP, analogous to proteins M1 and H, is also present at the bacterial surface, stationary phase AP1 bacteria were incubated with a rabbit antiserum raised against sHIP or with preimmune serum from the same rabbit. Protein G binds rabbit IgG antibodies with high affinity (61), and after careful washing, radiolabeled protein G was added to the bacterial suspensions to detect IgG associated with the bacterial surface. Compared with preincubations with non-immune serum, the binding of protein G was consistently higher to bacteria pretreated with immune serum against sHIP, 28.7 ± 8.6% higher radioactivity in six separate experiments. When analyzed with paired t testing, the difference was highly significant (p = 0.0012), demonstrating that sSHIP is present at the surface of AP1 bacteria.
The Structure of sHIP Displays a Tetramer of Four Two-helix Bundles—To gain further insight into the properties of sHIP, the three-dimensional structure was determined by x-ray crystallography. sHIP was cloned from AP1 DNA, expressed in E. coli, and purified to homogeneity by a combination of immobilized metal ion affinity chromatography and reverse phase chromatography. The sequence of the construct was verified by nucleotide sequencing, and the correct mass of the protein was confirmed by mass spectrometry. sHIP was shown to crystallize as a homotetramer, and the crystal structure was determined to a resolution of 2.4 Å by single isomorphous replacement with anomalous scattering phasing using selenomethionine-labeled protein. Refinement led to a model that consists of 3093 protein atoms and 55 water molecules (Table 1). Final electron density

**TABLE 1**

| Data collection and refinement statistics | Native | Protein | SeMet |
|------------------------------------------|--------|--------|-------|
| **Data collection**                      |        |        |       |
| Beamline                                  | BESSY BL14.1 | BESSY BL14.1 |
| Wavelength (Å)                            | 0.91841 | 0.97981 |
| Space group                               | P1211  | P1211  |
| Cell dimensions                           | a, b, c (Å) | 49.55, 111.2, 51.14 | 51.82, 110.26, 51.24 |
| a, b, γ (degrees)                         | 90, 108, 90 | 90.0, 106.02, 90.0 |
| Resolution range (Å)**                    | 50.241 (5.55-5.241) | 45.39-3.1 (3.29-3.10) |
| R_sym (%)                                 | 7.8 (56.7) | 10.5 (65.0) |
| I/σ(I)**                                  | 15.01 (2.88) | 8.42 (1.70) |
| Completeness (%)                          | 98.8 (97.4) | 96.1 (93.1) |
| Multiplicity                              | 3.85 | 2.14 |
| **Refinement**                            |        |        |       |
| Resolution range (Å)**                    | 48.63-2.41 (2.47-2.41) |
| No. of reflections                        | 19,235 (13999) |
| R_work (%)                                | 22.9 (30.6) |
| R_free (%)                                | 26.9 (36.9) |
| No. of atoms                              | Protein | 3093 |
|                                         | Water | 55 |
| B-factors (Å²)                            | Protein | 61.37 |
|                                         | Water | 42.77 |
| Root mean square deviation stereochemistry |        |        |       |
| Bond lengths (Å)                          | 0.014 |
| Bond angles (degrees)                     | 1.654 |
| Ramachandran validation                   |        |        |       |
| Favored regions (%)                       | 96.94 |
| Allowed regions (%)                       | 3.06 |
| Non-allowed regions (%)                   | 0.0 |
| **a** Values for the highest resolution shell are indicated in parentheses. |

The Structure of sHIP Displays a Tetramer of Four Two-helix Bundles—To gain further insight into the properties of sHIP, the three-dimensional structure was determined by x-ray crystallography. sHIP was cloned from AP1 DNA, expressed in E. coli, and purified to homogeneity by a combination of immobilized metal ion affinity chromatography and reverse phase chromatography. The sequence of the construct was verified by nucleotide sequencing, and the correct mass of the protein was confirmed by mass spectrometry. sHIP was shown to crystallize as a homotetramer, and the crystal structure was determined to a resolution of 2.4 Å by single isomorphous replacement with anomalous scattering phasing using selenomethionine-labeled protein. Refinement led to a model that consists of 3093 protein atoms and 55 water molecules (Table 1). Final electron density replicates. The media were concentrated, dialyzed, and trypsin-digested, and the resulting peptides were analyzed with shotgun MS. Proteins were identified and quantified using a 1% false discovery rate with the OpenMS pipeline (75). Shown is average sHIP abundance of the biological replicates normalized to the total ion count of each sample. B. S. pyogenes strain AP1 was grown for 9 h, and samples of cells and medium were collected in triplicates at 0, 1.5, 3, 4.5, 6, 7.5, and 9 h. The A_{620 nm} is indicated with black spheres (left-hand axis), and the respective cfu/ml values are shown with white squares (right-hand axis). C, the amount of sHIP was measured in the cell (black bars, left-hand axis) and medium (black spheres, right-hand axis) fractions by SRM-MS. The amount of sHIP in the medium is compared with that of the known secreted S. pyogenes virulence factor SmeZ (Spy1998) (light gray triangles, right-hand axis). D, the amounts of M1 protein (Spy2018) and protein H were similarly measured in the cell and medium fractions by SRM-MS and AQUA peptides for comparison. In C and D, bars indicate the amount of protein in the cell fraction (left-hand axis, pmol in total fraction), and lines show the amount of protein in the medium fraction (right-hand axis, pmol in total fraction).

**FIGURE 1.** Levels of extracellular sHIP synthesized by S. pyogenes strains SF370 and AP1 and the amount of sHIP, the streptococcal mitogenic exotoxin Z (SmeZ), M1 protein, and protein H in strain AP1 measured by SRM-MS and heavy labeled peptides. A, culture media (TH broth) of strains SF370 and AP1 were collected at stationary growth phase in two biological replicates. The media were concentrated, dialyzed, and trypsin-digested, and the resulting peptides were analyzed with shotgun MS. Proteins were identified and quantified using a 1% false discovery rate with the OpenMS pipeline (75). Shown is average sHIP abundance of the biological replicates normalized to the total ion count of each sample. B. S. pyogenes strain AP1 was grown for 9 h, and samples of cells and medium were collected in triplicates at 0, 1.5, 3, 4.5, 6, 7.5, and 9 h. The A_{620 nm} is indicated with black spheres (left-hand axis), and the respective cfu/ml values are shown with white squares (right-hand axis). C, the amount of sHIP was measured in the cell (black bars, left-hand axis) and medium (black spheres, right-hand axis) fractions by SRM-MS. The amount of sHIP in the medium is compared with that of the known secreted S. pyogenes virulence factor SmeZ (Spy1998) (light gray triangles, right-hand axis). D, the amounts of M1 protein (Spy2018) and protein H were similarly measured in the cell and medium fractions by SRM-MS and AQUA peptides for comparison. In C and D, bars indicate the amount of protein in the cell fraction (left-hand axis, pmol in total fraction), and lines show the amount of protein in the medium fraction (right-hand axis, pmol in total fraction).
maps were of high quality; there were, however, no interpretable densities for residues located in the 12-residue loop region, including residues Trp60, Ala61 (chain A), Trp60, Ala61, Asp52 (chain B), Leu55, Ala56, Gln38, Pro60, Trp60, Ala61, Asp52 (chain C), and Trp60 (chain D). All non-glycine residues exhibit main-chain angles in the allowed regions of the Ramachandran plot as defined by Molprobity (37) (Table 1). The overall structure of sHIP reveals a homotrimer composed of four two-helix bundles. Due to interactions at the tetramer interface (discussed below), the observed tetramer can be described as a dimer of dimers (Fig. 3A). The sSHIP monomer forms an elongated helix-loop-helix structure consisting of two antiparallel \( \alpha \)-helices connected by a 12-residue loop segment. The absence of interpretable electron density in this region indicates flexibility of the loop. The remaining residues localized in the loop have high \( B \)-factors, indicating a high degree of flexibility. The fold of the four monomers is essentially identical, including the side-chain orientations. It should be noted that the individual helices make very few contacts within each monomer, whereas a number of interactions are observed between the neighboring monomers in the formation of the dimers. The analysis of protein interfaces, performed by the PISA server (62), strongly suggests that both dimers, A/B and C/D, are stable in solution, indicated by large buried surface areas of 5470 and 5320 \( \AA^2 \) for the dimers A/B and C/D, respectively. An identical network of interchain hydrogen bonds is observed for both dimers of sSHIP. An identical network of interchain hydrogen bonds is observed for both dimers of sSHIP. Sedimentation velocity experiments performed with a 0.5 mM concentration of the molecule. Sedimentation velocity experiments performed with a 0.5 mM concentration of the molecule.

**FIGURE 2. Detection of sHIP in S. pyogenes growth medium.** One ml of sterile filtered growth media from the indicated time points was applied to PVDF membranes. The membrane was probed with rabbit antibodies raised against sSHIP (1:1000) or with a preimmune rabbit antiserum (1:1000). Protein sSHIP (50 ng) was used as a positive control, and TH broth was used as a negative control.

of dimers with a predominantly buried hydrophobic surface area of 12,720 \( \AA^2 \), as calculated using the PISA server (62). The hydrophobic patch is formed by amino acids with largely non-polar side chains, such as Leu84, Leu89, Tyr95, and Met98 (Fig. 3B). An example of the quality of the electron density map is visualized for one of the helices in the interface region (Fig. 3C). The three-dimensional structure for sSHIP shows no structural similarity to any other protein from *S. pyogenes* by using the Dali server (38) with our structure as input (Protein Data Bank code 4MER), and when the sequence of sSHIP was compared with all deposited sequences of *S. pyogenes* in UniProt, no other homologous proteins were detected. However, the structural comparison indicated similarities to the helix-loop-helix motif found in the bacterial adhesion factor FadA from *Fusobacterium nucleatum* (Protein Data Bank code 3ETW) (63). The root mean square deviation for the main-chain atoms between sSHIP and FadA is 3.9 \( \AA \). Because sSHIP only shows 8% sequence identity to the FadA, it was not possible to identify the structural relationship based solely on comparisons of primary structures. Although three-dimensional superimposition of these two structural motifs, calculated by the Dali server, reveals similar helix-loop-helix topologies, the structures are in fact quite distinct (Fig. 3D). The first significant difference is observed in the N-terminal helical region of the structures. In FadA, it is formed by one elongated, slightly curved \( \alpha \)-helix, whereas in sSHIP, we can distinguish three \( \alpha \)-helical segments in this region, corresponding to a kinked helix 1 (Lys3–His36), a linear helix 2 (His36–Ser49), and a curved helix 3 (Ser49–Asn57). Second, in the FadA structure, the antiparallel helices are in closer proximity than the corresponding helices in the sSHIP structure, as evidenced by shorter distances between structurally equivalent positions of \( \alpha \)-carbons. Third, differences are observed in the loop region connecting the two helices. In FadA, this region is a well defined short hairpin loop, whereas in sSHIP, the related loop is eight residues longer and poorly defined. Different crystal packing effects for the respective structures can explain the observed differences for the loop regions.

**sSHIP Interacts with HRG**—Several virulence factors have been shown to be involved in direct interactions with proteins from the human host. These protein-protein interactions are central to their functional properties. In order to explore possible interactions between sSHIP and human host proteins, we performed AP-MS with TAP-tagged sSHIP in human plasma (Fig. 5 and Table 2). Interacting protein hits were filtered using both the CompPASS (46) and SAINT (45) algorithms. Only proteins with a significance score above the threshold value using the combined score for the two algorithms were considered to be potential interacting candidates (Table 2). There are altogether eight significant hits above the threshold value, including HRG, the trypsin-inhibiting proteins \( \alpha \)-1-antitrypsin and AMBP, the complement proteins C3 and complement factor H, as well as von Willebrandt factor, serum albumin, and apolipoprotein A-1 (Fig. 5 and Table 2). Of these proteins, HRG, serum albumin, \( \alpha \)-1-antitrypsin, apolipoprotein A-1, and the complement proteins C3 and complement factor H have previously been shown to interact either with intact *S. pyogenes* bacteria or individual *S. pyogenes* proteins (24, 64–68). Because HRG, detected in several AP-MS experiments with a highly
significant score (Table 2), has been shown to display broad antimicrobial activity (48), including killing of *S. pyogenes* (24), the interaction between sSHIP and HRG was further investigated by biophysical means. In order to validate the interaction observed by AP-MS, SPR experiments (69) were performed. Human recombinant HRG was immobilized on the surface of a CM3 sensor chip, and sSHIP was injected into the flow cell at concentrations ranging from 4 to 100 \( \mu M \). Binding sensorgrams for each analyte concentration were recorded, and the equilibrium response values at the end of each injection were plotted versus concentrations. The fit of the data to a 1:1 steady-state binding model yielded a dissociation constant of 12 \( \mu M \) (Fig. 6A). To ensure that mass transfer effects do not limit binding interactions, the experiments were performed at two flow rates, 30 and 60 \( \mu l/min \). Comparable affinities were observed under both flow rate conditions. In order to address the specificity in interactions involving sSHIP, we performed SPR experiments between sSHIP and streptococcal protein G and human ubiquitin, respectively, indicating no binding to these two control pro-
teins (data not shown). In addition, ITC experiments were performed using intact HRG and sHIP at pH 5.5 and 7.5. These experiments showed that sHIP binds to HRG with similar affinities at both pH values with a $K_d = 130 \text{ nM}$, using a single-site binding model, at pH 5.5 and $K_d = 200 \text{ nM}$ and $K_d = 40 \text{ \mu M}$, indicating two independent binding sites, at pH 7.5 (Fig. 6, B and C). Furthermore, ITC experiments using a peptide derived from the histidine-rich region of HRG, HRGsp, containing a heparin-binding motif (48), showed that sHIP interacts with this region. The interaction between protein sSHIP and HRGsp was measured by ITC and indicated a binding mode where the HRG peptide harbors two independent interacting motifs that bind to one sSHIP molecule (stoichiometry of HRGsp/sSHIP = 1:1). The affinities for the two independent sites are $K_d = 12 \text{ nM}$ and $K_d = 500 \text{ nM}$, respectively (Fig. 6D). Combined, the data verify that sHIP binds to HRG and that the histidine-rich region is important for the interaction.

**sSHIP Inhibits the Antibacterial Activity of HRG and an HRG-derived Peptide**—As mentioned above, HRG has previously been shown to kill *S. pyogenes* AP1 bacteria (24). To examine whether the binding of sSHIP to HRG inhibits the antibacterial activity of HRG, we assessed the effect of sSHIP in a bactericidal assay. As shown in Fig. 7A, HRG was able to kill AP1 bacteria at pH 5.5, as reported previously (24). In the presence of sSHIP, the antibacterial activity of HRG at a concentration of 0.45 \( \mu \text{M} \) was inhibited (Fig. 7B). To investigate the inhibitory capacity of sSHIP more in detail, we used a peptide derived from HRG that has been shown to exert antibacterial activity (48). This peptide, HRGlp, was tested and found to efficiently kill AP1 bacteria at pH 5.5 (Fig. 7C). The antibacterial activity of the peptide was inhibited by sSHIP at a bactericidal concentration (3.5 \( \mu \text{M} \)) in a dose-dependent manner (Fig. 7D). These experiments demonstrate that the binding of sSHIP to intact HRG and an HRG-derived peptide inhibits their antibacterial activity.

**Patients with Invasive *S. pyogenes* Infection Respond with Antibody Production against sSHIP**—The presence of sSHIP in the growth medium and at the bacterial surface of the virulent and invasive AP1 strain prompted us to investigate whether an immune response against sSHIP could be related to the severity of the infection. The antibody response against sSHIP was therefore investigated using ELISA by measuring sSHIP IgG antibody titers in serum samples of patients with superficial *S. pyogenes* skin infection (erysipelas) or deep tissue infection combined with bacteremia. Specific anti-sSHIP antibody levels were determined in acute-phase and convalescence sera, and the results showed that none of eight patients with superficial infection responded with antibody production against sSHIP clearly above the level of the acute-phase serum. In contrast, three of six patients with invasive infection had a 4-fold titer increase (Fig. 8), and statistical analysis of the two patient groups with the Wilcoxon signed rank test showed a significant difference ($p = 0.0313$). Moreover, in most cases acute-phase sera from patients with invasive infection showed higher anti-sSHIP IgG titers compared with sera from patients with superficial infection. These results demonstrate that an antibody response against sSHIP is initiated when *S. pyogenes* penetrates the natural barriers of its human host and that this response comes at an early phase of infection. Interestingly, a similar pattern has previously been reported for several well established *S. pyogenes* virulence factors (70).

**DISCUSSION**

Bacterial infections represent a major threat to humans, a threat that has become aggravated by the alarming and ongoing increase of antibiotic resistance. This situation will require the identification of novel preventive, diagnostic, and therapeutic strategies in order to successfully treat bacterial infections in the future. To achieve this goal, we need to better understand the complex molecular interplay between bacterial pathogens and their human host and to define the molecular basis for virulence. *S. pyogenes* is one of the most significant bacterial pathogens in the human population, and a starting point for the present study was the observation that the bacterial proteins released into the growth medium were different in the highly virulent AP1 strain compared with the low virulence SF370 strain. In particular, using mass spectrometry-based proteomics, we found that the protein sSHIP was present in high amounts in stationary growth medium of AP1 bacteria but at much lower concentrations in stationary medium of SF370. This indicated that sSHIP could play a role in *S. pyogenes* virulence, which motivated a thorough structural and functional characterization of the protein as well as an analysis of the antibody response against sSHIP in patients with superficial or invasive infection.

Protein sSHIP is a small acidic protein of 98 amino acid residues. Sequence analysis using SignalP (54) revealed that the protein is not predicted to contain a classical signal sequence. However, using SRM-MS, we could show that protein sSHIP appears in the AP1 growth medium after 3 h ($A_{420\text{ nm}}$ of 0.145) and then steadily continues to increase throughout the 9 h of growth. Protein sSHIP is found in both the cell-associated and growth medium fractions, and the amount of sSHIP in the medium compartment is similar to the secreted mitogenic exotoxin SmeZ (Fig. 1C). Furthermore, the overall abundance pro-

| Protein                      | Abbreviation | UniProt ID | 20 °C ComPASS/SAINT | 37 °C ComPASS/SAINT |
|------------------------------|--------------|------------|---------------------|---------------------|
| Complement C3                | CO3          | P01024     | 15.3/1              | 11.7/1              |
| Histidine-rich glycoprotein  | HRG          | P04196     | 8.0/1               | 3.3/1               |
| Serum albumin                | ALBU         | P02768     | 2.2/1               | 5.5/1               |
| von Willebrand factor        | VWF          | P04275     | 3.0/1               | ND*                 |
| Protein AMBP                 | AMBP         | P02760     | 2.5/1               | 1.7/1               |
| α-1-Antitrypsin              | A1AT         | P01009     | 1.5/1               | 1.7/1               |
| Complement factor H          | CFAH         | P08603     | 1.1/1               | 1.3/1               |
| Apolipoprotein A-I           | APOA1        | P02647     | ND                  | 1/1                 |

* ND, not detected.

**TABLE 2**

Human plasma proteins interacting with sSHIP at 20 and 37 °C and their respective ComPASS (46) and SAINT (45) significance scores (reported in order of significance)
Structure and Function of Protein sHIP

A

Normalized RU

sHIP concentration (µM)

0 20 40 60 80 100

0.0 0.2 0.4 0.6 0.8 1.0

B

k_{on} = 130 nM

µcal/sec

kcal/mole of injectant

0.0 0.2 0.4 0.6 0.8

Molar ratio (HRG to sHIP)

C

µcal/sec

k_{on} = 200 nM

k_{off} = 40 µM

D

Thermodynamic Parameters:

N_1 = 0.5±0.1

N_2 = 0.8±0.1

k_{on} = 12±4 nM

k_{off} = 500±100 nM

ΔH_1 = -14±1.2 kcal/mol

ΔH_2 = -33±3 kcal/mol

Molar ratio (HRG to sHIP)

Molar ratio (peptide to protein)
file of sHIP resembles the profile for the surface-associated proteins H and M1 (Fig. 1D). It has previously been reported that *Bacillus subtilis* proteins without a signal sequence but with a high abundance in the cytoplasm can be detected in the extracellular medium (71). Furthermore, these proteins, as well as sHIP, show low scores using a prediction method for proteins secreted by signal peptide-independent mechanisms (72), suggesting that these proteins are secreted through a yet unknown mechanism.

The structure of sHIP consists of a tetramer of four helix-loop-helix motifs with the loop regions connecting the helices displaying a high degree of flexibility. The structural characterization of sHIP is particularly interesting because sHIP shows no significant sequence similarity to any other *S. pyogenes* protein. Through use of the DALI server (38), we were able to identify a similar helix-loop-helix motif in the adhesion factor FadA from *F. nucleatum* (63). Despite similar helix-loop-helix arrangements, there are significant differences in conformation and packing of the helices as well as in their respective connecting loops. However, the largest difference is related to the oligomeric states of the two proteins. In FadA, the helix-loop-helix monomers are involved in head-to-tail interactions resulting in the formation of elongated polymers (63), whereas the sHIP monomers assemble into a compact tetrameric quaternary structure.

In order to identify possible interactions between sHIP and human proteins, affinity pull-down assays using human plasma with sHIP as bait were performed, resulting in eight significant hits (Table 2). Two of these proteins are complement factors C3 and H, which might indicate that sHIP could have an impact on complement function. Apart from these complement proteins, one of the most prominent hits, and the only host protein with an established antibacterial activity against *S. pyogenes*, was HRG (24). SPR experiments showed that full-length HRG binds

![Figure 6](image-url) **FIGURE 6.** Biophysical studies of the interaction between sHIP and intact HRG and an HRG peptide. A, the interaction between immobilized recombinant HRG and recombinant sHIP in solution was recorded by SPR (Biacore). Experiments were carried out at 25 °C in Dulbecco’s PBS buffer, pH 7.3. The normalized response units (RU) at equilibrium are plotted versus concentration of sHIP (µM). The data were fit to a 1:1 steady-state binding model, and the dissociation constant ($K_d$) was found to be $12 \pm 1$ µM. B, ITC showing the binding between protein sHIP and intact HRG at pH 5.5. C, ITC experiments showing the binding between protein sHIP and intact HRG at pH 7.5. D, ITC experiments showing the binding between protein sHIP and the HRG peptide. The raw data of the experiments are presented in the top panel. The area below each injection peak is equal to the total heat released for that injection. When this integrated heat is plotted against the molar ratio of titrant added to the peptide solution in the cell, a complete binding isotherm for the interaction is obtained (bottom panel). A model for either one binding site (B) or two independent sites (C and D) was used to fit the data. The solid line is the calculated curve using the best fit parameters. The thermodynamic parameters for the interaction are shown in the bottom panel.

![Figure 7](image-url) **FIGURE 7.** sHIP inhibits the bactericidal activity of HRG and an HRG-derived peptide. A, *S. pyogenes* AP1 bacteria ($2 \times 10^6$ cfu/ml) were incubated with various concentrations of HRG, and cfu were determined. B, the bactericidal effect of HRG at a concentration of 0.45 µM was inhibited with sHIP at the indicated concentrations. C, *S. pyogenes* AP1 bacteria ($2 \times 10^6$ cfu/ml) were incubated with various concentrations of the HRG peptide, and cfu were determined. D, the bactericidal effect of the peptide at a concentration of 3.5 µM was inhibited with sHIP at the indicated concentrations. Experiments were repeated three times, and mean values ± S.D. (error bars) are shown.
Structure and Function of Protein sHIP

![Graph showing the affinity and binding of sHIP to HRG.]

**FIGURE 8.** Pooled human immunoglobulin G (Privigen; 100 mg/ml) was used as a reference. This IgG was serially diluted in 2-fold steps to a final dilution of 1:8000 to generate a standard curve, and the IgG antibodies bound to sHIP were detected with peroxidase-labeled protein G. The sera from the patients were diluted 1:100 and analyzed as above. Bound IgG was compared with the standard curve, and the graph displays the 2-fold dilution steps of Privigen to which the patient sera (diluted 1:100) are equivalent.

The gene encoding sHIP (M5005_Spy_1730) is located between the genes of the mga regulon, which harbors genes encoding several important virulence factors (M1 protein, proteins H and SIC, and C5a peptidase), and the gene encoding SpeB, a cysteine protease and virulence determinant. There are in total 14 genes found in this region, including several uncharacterized proteins, such as sHIP, but also a number of genes encoding for proteins involved in protein transport and efflux (M5005_Spy_1726, Q99XU4; M5005_Spy_1727, Q99XU3; M5005_Spy_1728, Q99XU2). In a recent study (74), the relevance of several *S. pyogenes* genes, including sHIP, was tested. Transposon site hybridization was used to create a mutant library that was subsequently tested in human blood to identify genes important for *S. pyogenes* survival in this environment. In total, 81 gene knockouts resulted in reduced fitness in blood from at least two tested individuals. As expected, a knock-out of *mga* encoding Mga, a positive regulator of the *mga* regulon, created a mutant with reduced survival. In relation to the present work, it is interesting that another of the mutants that showed reduced fitness in human blood was a mutant in the gene encoding sHIP (designated M5005_Spy_1730 in the study by Le Breton et al. (74)). The demonstration here that patients with invasive and severe *S. pyogenes* infection are more prone to develop IgG antibodies against sHIP than patients with superficial infection further indicates a role for the protein in *S. pyogenes* pathogenesis. Finally, the demonstration that sHIP blocks the bactericidal activity of HRG provides a plausible explanation of the function of this novel extracellular protein and putative virulence determinant.

Acknowledgments—We thank the SyBIT project of SystemsX.ch for support and maintenance of the laboratory-internal computing infrastructure and the ITS HPC team (Brutus).

REFERENCES

1. Carapetis, J. R., Steer, A. C., Mulholland, E. K., and Weber, M. (2005) The global burden of group A streptococcal diseases. *Lancet Infect. Dis.* 5, 685–694

2. Ralph, A. P., and Carapetis, J. R. (2013) Group A streptococcal diseases and their global burden. *Curr. Topics Microbiol. Immunol.* 368, 1–27

3. Lancefield, R. C. (1962) Current knowledge of type-specific M antigens of group A streptococci. *J. Immunol.* 89, 307–313

4. Swanson, J., Hsu, K. C., and Gotschlich, E. C. (1969) Electron microscopic studies on streptococci. I. M antigen and their global burden. *J. Exp. Med.* 130, 1063–1091

5. Phillips, G. N., Jr., Flicker, P. F., Cohen, C., Manjula, B. N., and Fischetti, V. A. (1981) Streptococcal M protein: α-helical coiled-coil structure and arrangement on the cell surface. *Proc. Natl. Acad. Sci. U.S.A.* 78, 4689–4693

6. Wessels, M. R., Moses, A. E., Goldberg, J. B., and DiCesare, T. J. (1991) Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. *Proc. Natl. Acad. Sci. U.S.A.* 88, 8317–8321

7. Talay, S. R., Valentin-Weigand, P., Timmis, K. N., and Chhatwal, G. S. (1994) Domain structure and conserved epitopes of Sfb protein, the fibronectin-binding adhesin of *Streptococcus pyogenes*. *Mol. Microbiol.* 13, 531–539

8. Jaffe, J., Natanson-Yaron, S., Caparon, M. G., and Hanski, E. (1996) Protein F2, a novel fibronectin-binding protein from *Streptococcus pyogenes*, possesses two binding domains. *Mol. Microbiol.* 21, 373–384
Structure and Function of Protein sHIP

50. Ortega, A., Amorós, D., and García de la Torre, J. (2011) Prediction of hydrodynamic and other solution properties of rigid proteins from atomic- and residue-level models. *Biophys. J.* 101, 892–898

51. Wiseman, T., Williston, S., Brandts, I. F., and Lin, L. N. (1989) Rapid measurement of binding constants and heats of binding using a new titration calorimeter. *Anal. Biochem.* 179, 131–137

52. Holden, M. T., Scott, A., Cherevach, I., Chillingworth, T., Churcher, C., Cronin, A., Dowd, L., Feltwell, T., Harlin, N., Holroyd, S., Jagels, K., Moule, S., Mungall, K., Quail, M. A., Price, C., Rabinowitsch, E., Sharp, S., Skelton, J., Whitehead, S., Barrett, B. G., Keohé, M., and Parkhill, J. (2007) Complete genome of acute rheumatic fever-associated serotype M5 *Streptococcus pyogenes* strain manfredo. *J. Bacteriol.* 189, 1473–1477

53. Green, N. M., Zhang, S., Porcella, S. F., Nagiec, M. J., Barbian, K. D., Beres, S. B., LeFebvre, R. B., and Musser, J. M. (2005) Genomic sequence of a serotype M28 strain of group A streptococcus: potential new insights into puerperal sepsis and bacterial disease specificity. *J. Infect. Dis.* 192, 760–770

54. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786

55. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., and Gygi, S. P. (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. *Proc. Natl. Acad. Sci. U.S.A.* 100, 6940–6945

56. Malmström, J., Beck, M., Schmidt, A., Lange, V., Deutsch, E. W., and Aebersold, R. (2009) Proteome-wide cellular protein concentrations of the human pathogen *Leptospira interrogans*. *Nature* 460, 762–765

57. Wollein Waldetoft, K., Karlsson, C., Gram, M., Malmström, J., Mörgelin, M., Frick, I. M., and Björck, L. (2014) Surface proteins of group G *Streptococcus* in different phases of growth: patterns of production and implications for the host-bacteria relationship. *Microbiology* 160, 279–286

58. Kamezawa, Y., Nakahara, T., Nakano, S., Abe, Y., Nozaki-Renard, J., and Isono, T. (1997) *Streptococcus* mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of *Streptococcus pyogenes*. *Infect. Immun.* 65, 3828–3833

59. Akesson, P., Cooney, J., Kishimoto, F., and Björck, L. (1990) Protein H: a novel IgG binding bacterial protein. *Mol. Immunol.* 27, 523–531

60. Berge, A., and Björck, L. (1995) *Streptococcus* cysteine proteinase releases biologically active fragments of streptococcal surface proteins. *J. Biol. Chem.* 270, 9862–9867

61. Akerström, B., Brodin, T., Reis, K., and Björck, L. (1985) Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. *J. Immunol.* 135, 2589–2592

62. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. *J. Mol. Biol.* 372, 774–797

63. Nithianantham, S., Xu, M., Yamada, M., Ikegami, A., Shoham, M., and Han, Y. W. (2009) Crystal structure of FadA adhesin from *Fusobacterium nucleatum* reveals a novel oligomerization motif, the leucine chain. *J. Biol. Chem.* 284, 3865–3872

64. Weinert Niclasen, L., Olsen, J. G., Dagil, R., Qing, Z., Sørensen, O. E., and Krangel, B. B. (2011) *Streptococcus* pyrogenic exotoxin B (SpeB) boosts the contact system via binding of α-1 antitrypsin. *Biochem. J.* 434, 123–132

65. Reuter, M., Caswell, C. C., Lukomski, S., and Zipfel, P. F. (2010) Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scll) via their conserved C termini allows control of the complement cascade at multiple levels. *J. Biol. Chem.* 285, 38473–38485

66. Rosales, C., Gillard, B. K., Courtney, H. S., Blanco-Vaca, F., and Pownall, H. I. (2009) Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. *Biochemistry* 48, 8070–8076

67. Schmidt, K. H., and Wadström, T. (1990) A secreted receptor related to M1 protein of *Streptococcus pyogenes* binds to fibrinogen, IgG, and albumin. *Zentralbl. Bakteriol.* 273, 216–228

68. Sjöholm, K., Karlsson, C., Linder, A., and Malmström, J. (2014) A comprehensive analysis of the *Streptococcus pyogenes* and human plasma protein interaction network. *Mol. Bio syst.* 10.1039/C3MB70555B

69. Johnsson, B., Löfås, S., and Lindquist, G. (1991) Immobilization of proteins to a carboxymethyl-dextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. *Anal. Biochem.* 198, 268–277

70. Akesson, P., Rasmussen, M., Mascini, E., von Pawel-Rammingen, U., Janulczyk, R., Collins, M., Olsen, A., Mattsson, E., Olsson, M. L., Björck, L., and Christenson, B. (2004) Low antibody levels against cell wall-attached proteins of *Streptococcus pyogenes* predispose for severe invasive disease. *J. Infect. Dis.* 189, 797–804

71. Böttner, K., Bernhardt, J., Scharf, C., Schmid, R., Mäder, U., Eymann, C., Antelmann, H., Völker, A., Völker, U., and Hecker, M. (2001) A comprehensive two-dimensional map of cytosolic proteins of *Bacillus subtilis*. *Electrophoresis* 22, 2908–2935

72. Bentdsen, J. D., Kiemer, L., Fausboll, A., and Brunak, S. (2005) Non-classical protein secretion in bacteria. *BMC Microbiol.* 5, 58

73. Raju, R., Weiner, M., and Enquist, J. (1976) Quantitation of local acidosis and hypoxia produced by infection. *Am. J. Surg.* 132, 64–66

74. Le Breton, Y., Mistry, P., Valdes, K. M., Quigley, J., Kumar, N., Tettelin, H., and Mclver, K. S. (2013) Genome-wide identification of genes required for fitness of group A *Streptococcus* in human blood. *Infect. Immun.* 81, 862–875

75. Weisser, H., Nohsens, S., Grossmann, J., Nilse, L., Quandt, A., Brauer, H., Sturm, M., Kenar, E., Kohlbacher, O., Aebersold, R., and Malmström, L. (2013) An automated pipeline for high-throughput label-free quantitative proteomics. *J. Proteome Res.* 12, 1628–1644

76. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 13, 2498–2504

77. Warsow, G., Greber, B., Falk, S. S., Harder, C., Siatkowski, M., Schordan, S., Som, A., Endlich, N., Scholer, H., Reipsilber, D., Endlich, K., and Fuellen, G. (2010) ExprEssence: revealing the essence of differential experimental data in the context of an interaction/regulation network. *BMC Syst. Biol.* 4, 164